Overview

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

Status:
Not yet recruiting
Trial end date:
2024-01-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation